 Drug Repurposing Market Insights, Competitive Landscape, and Market Forecast - 2033
The global drug repurposing market is witnessing steady growth, underpinned by lower development costs and faster regulatory pathways compared with novel drug development amid demand across establi... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global drug repurposing market is witnessing steady growth, underpinned by lower development costs and faster regulatory pathways compared with novel drug development amid demand across established and emerging end-use segments. End users are placing greater emphasis on consistent performance and long-term value, prompting manufacturers to expand investment in clinical and regulatory development. Ongoing improvements in clinical and regulatory development are further strengthening product reliability and the overall customer experience. The global drug repurposing market is expected to be valued at US$ 35.80 Bn in 2026 and is projected to reach US$ 47.75 Bn by 2033, growing at a CAGR of 4.2% between 2026 and 2033.Market Insights: The drug repurposing sector is undergoing steady transformation as manufacturers adapt their offerings to changing requirements across Disease Area, Drug Type and End Use. Rising demand for reliable, well-differentiated products is driving continued investment in clinical and regulatory development, even as buyers weigh lifecycle costs more closely alongside purchase price. Manufacturers are simultaneously expanding regional presence and after-sales support to reach a wider customer base, underscoring the growing role of service quality and technical expertise in supplier selection. Drivers: Growth in the market is chiefly driven by lower development costs and faster regulatory pathways compared with novel drug development, encouraging continued investment from both long-established manufacturers and new market entrants. Purchasing decisions increasingly reflect a focus on consistent performance, compliance requirements, and total lifecycle cost, while ongoing innovation is broadening the scope of viable applications across Disease Area, Drug Type and End Use. Increasing awareness among end users is supporting wider adoption across established and emerging use cases alike, sustaining demand over the forecast period. Business Opportunity: Significant opportunity within the market is linked to AI-assisted target identification and expanding oncology and rare-disease applications. Manufacturers investing in clinical and regulatory development, additional regional capacity, and stronger manufacturing and distribution stand to gain share as end-use demand continues to diversify. Additional upside is available through complementary service-based revenue streams such as maintenance, monitoring, and advisory support alongside core offerings. Region Analysis: North America and Europe continue to account for a substantial share of the drug repurposing market, aided by mature regulatory environments, established manufacturing and distribution networks, and consistent replacement demand. East Asia and South Asia & Oceania are emerging as key growth regions, supported by expanding local capacity, growing end-user awareness, and rising investment in regional distribution infrastructure. Meanwhile, Latin America and the Middle East & Africa are expected to add incremental growth through the forecast period as infrastructure improves and formal distribution channels expand. Key Players: • Eli Lilly and Company • Pfizer Inc. • Roche Holding AG • Novartis AG • Bayer AG • GSK plc • Amgen Inc. • Biogen Inc. • Teva Pharmaceutical Industries Ltd. • Vertex Pharmaceuticals Incorporated Segmentation: By Disease Area • Oncology • Neurology Disorders • Infectious Diseases • Cardiovascular Conditions • Metabolic Disorders • Others Therapeutic Areas By Drug Type • Conventional Small Molecules • Biologics and Peptide-based Drugs By End Use • Biopharmaceutical & Pharmaceutical Companies • Clinical Research Organizations (CROs) • Universities & Research Institutions By Regions • North America • Europe • East Asia • South Asia & Oceania • Latin America • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Drug Repurposing Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Drug Repurposing Market Outlook, 2020-2033 3.1. Global Drug Repurposing Market Outlook, by Disease Area, Value (US$ Bn), 2020-2033 3.1.1. Oncology 3.1.2. Neurology Disorders 3.1.3. Infectious Diseases 3.1.4. Cardiovascular Conditions 3.1.5. Metabolic Disorders 3.1.6. Others Therapeutic Areas 3.2. Global Drug Repurposing Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033 3.2.1. Conventional Small Molecules 3.2.2. Biologics and Peptide-based Drugs 3.3. Global Drug Repurposing Market Outlook, by End Use, Value (US$ Bn), 2020-2033 3.3.1. Biopharmaceutical & Pharmaceutical Companies 3.3.2. Clinical Research Organizations (CROs) 3.3.3. Universities & Research Institutions 3.4. Global Drug Repurposing Market Outlook, by Region, Value (US$ Bn), 2020-2033 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Latin America 3.4.5. Middle East & Africa 4. North America Drug Repurposing Market Outlook, 2020-2033 4.1. North America Drug Repurposing Market Outlook, by Disease Area, Value (US$ Bn), 2020-2033 4.1.1. Oncology 4.1.2. Neurology Disorders 4.1.3. Infectious Diseases 4.1.4. Cardiovascular Conditions 4.1.5. Metabolic Disorders 4.1.6. Others Therapeutic Areas 4.2. North America Drug Repurposing Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033 4.2.1. Conventional Small Molecules 4.2.2. Biologics and Peptide-based Drugs 4.3. North America Drug Repurposing Market Outlook, by End Use, Value (US$ Bn), 2020-2033 4.3.1. Biopharmaceutical & Pharmaceutical Companies 4.3.2. Clinical Research Organizations (CROs) 4.3.3. Universities & Research Institutions 4.4. North America Drug Repurposing Market Outlook, by Country, Value (US$ Bn), 2020-2033 4.4.1. U.S. Drug Repurposing Market Outlook, by Disease Area, 2020-2033 4.4.2. U.S. Drug Repurposing Market Outlook, by Drug Type, 2020-2033 4.4.3. U.S. Drug Repurposing Market Outlook, by End Use, 2020-2033 4.4.4. Canada Drug Repurposing Market Outlook, by Disease Area, 2020-2033 4.4.5. Canada Drug Repurposing Market Outlook, by Drug Type, 2020-2033 4.4.6. Canada Drug Repurposing Market Outlook, by End Use, 2020-2033 4.5. BPS Analysis/Market Attractiveness Analysis 5. Europe Drug Repurposing Market Outlook, 2020-2033 5.1. Europe Drug Repurposing Market Outlook, by Disease Area, Value (US$ Bn), 2020-2033 5.1.1. Oncology 5.1.2. Neurology Disorders 5.1.3. Infectious Diseases 5.1.4. Cardiovascular Conditions 5.1.5. Metabolic Disorders 5.1.6. Others Therapeutic Areas 5.2. Europe Drug Repurposing Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033 5.2.1. Conventional Small Molecules 5.2.2. Biologics and Peptide-based Drugs 5.3. Europe Drug Repurposing Market Outlook, by End Use, Value (US$ Bn), 2020-2033 5.3.1. Biopharmaceutical & Pharmaceutical Companies 5.3.2. Clinical Research Organizations (CROs) 5.3.3. Universities & Research Institutions 5.4. Europe Drug Repurposing Market Outlook, by Country, Value (US$ Bn), 2020-2033 5.4.1. Germany Drug Repurposing Market Outlook, by Disease Area, 2020-2033 5.4.2. Germany Drug Repurposing Market Outlook, by Drug Type, 2020-2033 5.4.3. Germany Drug Repurposing Market Outlook, by End Use, 2020-2033 5.4.4. Italy Drug Repurposing Market Outlook, by Disease Area, 2020-2033 5.4.5. Italy Drug Repurposing Market Outlook, by Drug Type, 2020-2033 5.4.6. Italy Drug Repurposing Market Outlook, by End Use, 2020-2033 5.4.7. France Drug Repurposing Market Outlook, by Disease Area, 2020-2033 5.4.8. France Drug Repurposing Market Outlook, by Drug Type, 2020-2033 5.4.9. France Drug Repurposing Market Outlook, by End Use, 2020-2033 5.4.10. U.K. Drug Repurposing Market Outlook, by Disease Area, 2020-2033 5.4.11. U.K. Drug Repurposing Market Outlook, by Drug Type, 2020-2033 5.4.12. U.K. Drug Repurposing Market Outlook, by End Use, 2020-2033 5.4.13. Spain Drug Repurposing Market Outlook, by Disease Area, 2020-2033 5.4.14. Spain Drug Repurposing Market Outlook, by Drug Type, 2020-2033 5.4.15. Spain Drug Repurposing Market Outlook, by End Use, 2020-2033 5.4.16. Russia Drug Repurposing Market Outlook, by Disease Area, 2020-2033 5.4.17. Russia Drug Repurposing Market Outlook, by Drug Type, 2020-2033 5.4.18. Russia Drug Repurposing Market Outlook, by End Use, 2020-2033 5.4.19. Rest of Europe Drug Repurposing Market Outlook, by Disease Area, 2020-2033 5.4.20. Rest of Europe Drug Repurposing Market Outlook, by Drug Type, 2020-2033 5.4.21. Rest of Europe Drug Repurposing Market Outlook, by End Use, 2020-2033 5.5. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Drug Repurposing Market Outlook, 2020-2033 6.1. Asia Pacific Drug Repurposing Market Outlook, by Disease Area, Value (US$ Bn), 2020-2033 6.1.1. Oncology 6.1.2. Neurology Disorders 6.1.3. Infectious Diseases 6.1.4. Cardiovascular Conditions 6.1.5. Metabolic Disorders 6.1.6. Others Therapeutic Areas 6.2. Asia Pacific Drug Repurposing Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033 6.2.1. Conventional Small Molecules 6.2.2. Biologics and Peptide-based Drugs 6.3. Asia Pacific Drug Repurposing Market Outlook, by End Use, Value (US$ Bn), 2020-2033 6.3.1. Biopharmaceutical & Pharmaceutical Companies 6.3.2. Clinical Research Organizations (CROs) 6.3.3. Universities & Research Institutions 6.4. Asia Pacific Drug Repurposing Market Outlook, by Country, Value (US$ Bn), 2020-2033 6.4.1. China Drug Repurposing Market Outlook, by Disease Area, 2020-2033 6.4.2. China Drug Repurposing Market Outlook, by Drug Type, 2020-2033 6.4.3. China Drug Repurposing Market Outlook, by End Use, 2020-2033 6.4.4. Japan Drug Repurposing Market Outlook, by Disease Area, 2020-2033 6.4.5. Japan Drug Repurposing Market Outlook, by Drug Type, 2020-2033 6.4.6. Japan Drug Repurposing Market Outlook, by End Use, 2020-2033 6.4.7. South Korea Drug Repurposing Market Outlook, by Disease Area, 2020-2033 6.4.8. South Korea Drug Repurposing Market Outlook, by Drug Type, 2020-2033 6.4.9. South Korea Drug Repurposing Market Outlook, by End Use, 2020-2033 6.4.10. India Drug Repurposing Market Outlook, by Disease Area, 2020-2033 6.4.11. India Drug Repurposing Market Outlook, by Drug Type, 2020-2033 6.4.12. India Drug Repurposing Market Outlook, by End Use, 2020-2033 6.4.13. Southeast Asia Drug Repurposing Market Outlook, by Disease Area, 2020-2033 6.4.14. Southeast Asia Drug Repurposing Market Outlook, by Drug Type, 2020-2033 6.4.15. Southeast Asia Drug Repurposing Market Outlook, by End Use, 2020-2033 6.4.16. Rest of SAO Drug Repurposing Market Outlook, by Disease Area, 2020-2033 6.4.17. Rest of SAO Drug Repurposing Market Outlook, by Drug Type, 2020-2033 6.4.18. Rest of SAO Drug Repurposing Market Outlook, by End Use, 2020-2033 6.5. BPS Analysis/Market Attractiveness Analysis 7. Latin America Drug Repurposing Market Outlook, 2020-2033 7.1. Latin America Drug Repurposing Market Outlook, by Disease Area, Value (US$ Bn), 2020-2033 7.1.1. Oncology 7.1.2. Neurology Disorders 7.1.3. Infectious Diseases 7.1.4. Cardiovascular Conditions 7.1.5. Metabolic Disorders 7.1.6. Others Therapeutic Areas 7.2. Latin America Drug Repurposing Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033 7.2.1. Conventional Small Molecules 7.2.2. Biologics and Peptide-based Drugs 7.3. Latin America Drug Repurposing Market Outlook, by End Use, Value (US$ Bn), 2020-2033 7.3.1. Biopharmaceutical & Pharmaceutical Companies 7.3.2. Clinical Research Organizations (CROs) 7.3.3. Universities & Research Institutions 7.4. Latin America Drug Repurposing Market Outlook, by Country, Value (US$ Bn), 2020-2033 7.4.1. Brazil Drug Repurposing Market Outlook, by Disease Area, 2020-2033 7.4.2. Brazil Drug Repurposing Market Outlook, by Drug Type, 2020-2033 7.4.3. Brazil Drug Repurposing Market Outlook, by End Use, 2020-2033 7.4.4. Mexico Drug Repurposing Market Outlook, by Disease Area, 2020-2033 7.4.5. Mexico Drug Repurposing Market Outlook, by Drug Type, 2020-2033 7.4.6. Mexico Drug Repurposing Market Outlook, by End Use, 2020-2033 7.4.7. Argentina Drug Repurposing Market Outlook, by Disease Area, 2020-2033 7.4.8. Argentina Drug Repurposing Market Outlook, by Drug Type, 2020-2033 7.4.9. Argentina Drug Repurposing Market Outlook, by End Use, 2020-2033 7.4.10. Rest of LATAM Drug Repurposing Market Outlook, by Disease Area, 2020-2033 7.4.11. Rest of LATAM Drug Repurposing Market Outlook, by Drug Type, 2020-2033 7.4.12. Rest of LATAM Drug Repurposing Market Outlook, by End Use, 2020-2033 7.5. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Drug Repurposing Market Outlook, 2020-2033 8.1. Middle East & Africa Drug Repurposing Market Outlook, by Disease Area, Value (US$ Bn), 2020-2033 8.1.1. Oncology 8.1.2. Neurology Disorders 8.1.3. Infectious Diseases 8.1.4. Cardiovascular Conditions 8.1.5. Metabolic Disorders 8.1.6. Others Therapeutic Areas 8.2. Middle East & Africa Drug Repurposing Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033 8.2.1. Conventional Small Molecules 8.2.2. Biologics and Peptide-based Drugs 8.3. Middle East & Africa Drug Repurposing Market Outlook, by End Use, Value (US$ Bn), 2020-2033 8.3.1. Biopharmaceutical & Pharmaceutical Companies 8.3.2. Clinical Research Organizations (CROs) 8.3.3. Universities & Research Institutions 8.4. Middle East & Africa Drug Repurposing Market Outlook, by Country, Value (US$ Bn), 2020-2033 8.4.1. GCC Drug Repurposing Market Outlook, by Disease Area, 2020-2033 8.4.2. GCC Drug Repurposing Market Outlook, by Drug Type, 2020-2033 8.4.3. GCC Drug Repurposing Market Outlook, by End Use, 2020-2033 8.4.4. South Africa Drug Repurposing Market Outlook, by Disease Area, 2020-2033 8.4.5. South Africa Drug Repurposing Market Outlook, by Drug Type, 2020-2033 8.4.6. South Africa Drug Repurposing Market Outlook, by End Use, 2020-2033 8.4.7. Egypt Drug Repurposing Market Outlook, by Disease Area, 2020-2033 8.4.8. Egypt Drug Repurposing Market Outlook, by Drug Type, 2020-2033 8.4.9. Egypt Drug Repurposing Market Outlook, by End Use, 2020-2033 8.4.10. Nigeria Drug Repurposing Market Outlook, by Disease Area, 2020-2033 8.4.11. Nigeria Drug Repurposing Market Outlook, by Drug Type, 2020-2033 8.4.12. Nigeria Drug Repurposing Market Outlook, by End Use, 2020-2033 8.4.13. Rest of Middle East Drug Repurposing Market Outlook, by Disease Area, 2020-2033 8.4.14. Rest of Middle East Drug Repurposing Market Outlook, by Drug Type, 2020-2033 8.4.15. Rest of Middle East Drug Repurposing Market Outlook, by End Use, 2020-2033 8.5. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Eli Lilly and Company 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. Pfizer Inc. 9.4.3. Roche Holding AG 9.4.4. Novartis AG 9.4.5. Bayer AG 9.4.6. GSK plc 9.4.7. Amgen Inc. 9.4.8. Biogen Inc. 9.4.9. Teva Pharmaceutical Industries Ltd. 9.4.10. Vertex Pharmaceuticals Incorporated 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
Fairfield Market Research社の 医薬品・バイオテクノロジー分野 での最新刊レポート
本レポートと同じKEY WORD（drug）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
